Drugs moving into the clinic: 23

By Mike Nagle

- Last updated on GMT

Related tags: Vaccine, Obesity, Cancer

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
NicoxUndisclosedCardiovascular - anti hypertensionTarget undisclosed but Nicox specialise in NO-donating drugs
XomaXOMA 052Metabolic - Type II diabetes monoclonal antibody targeting Interleukin-1 beta (IL-1 beta)
Arena Pharma- ceuticals APD791 Cardiovascular - arterial thrombo-embolic diseases Selective inverse inhibitor of the 5-HT2A serotonin receptor
Affiris Affitope AD01 CNS - Alzheimer's Only combats the disease-causing beta-amyloid (after it has separated into the brain fluid), irrespective of whether it is still present in the brain fluid, or has formed plaque deposits.
Cougar Biotechnology CB3304 Oncology - relapsed or refractory multiple myeloma alkaloid derived from opium to inhibit microtubule dynamics, block cell division (mitosis) and cause apoptosis.
Quigley Pharma QR-449 Metabolic Syndrome Broad spectrum compound that modifies levels of pro-inflammatory cytokines and other factors, e.g. Interleukin-6 (IL- 6)
NeuroSearch & Abbott ABT-560CNS neuronal nicotinic receptor (NNR) modulator
Medivation MDV3100 Oncology - hormone-refractory prostate cancer Androgen receptor (AR) inhibitor
Athersys ATHX-105 Metabolism - obesity Stimulates the 5HT2c serotonin receptor without activating 5HT2b - which can cause cardivascular side effects
Targacept TC-5619 CNS - Schizophrenia, Cognitive Impairment, Inflammation Neuronal nicotinic receptor (NNR) modulator - alpha7 subtype
Icagen ICA-105665 CNS - epilepsy activates subtypes of KCNQ ion channels
Novavax undisclosed Anti-infectives and Vaccines - fluvirus-like particle ("VLP") based pandemic influenza vaccine (H5N1 clade 2)

Related topics: Preclinical Research

Related news

Show more

Follow us


View more